RARE — ULTRAGENYX PHARMACEUTICAL IN

Ownership history in Bridgefront Capital, LLC  ·  3 quarters on record

This page tracks every 13F SEC filing in which Bridgefront Capital, LLC reported a position in ULTRAGENYX PHARMACEUTICAL IN (RARE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.14% (2023 Q2)
Avg. % of fund
0.11%
First filed
2020 Q4
Last filed
2025 Q3
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 9,385 +3,683 +64.6% 0.08% $282K $30.08
2023 Q2 ADDED 5,702 +3,212 +129.0% 0.14% $263K $46.13
2020 Q4 INITIATED 2,490 — — 0.12% $345K $138.43
% of Fund (quarterly)    RARE price (monthly, adj. close)

Other funds also holding RARE

As of 2025 Q4 — sorted by position size

GordonMD Global Investments LP 5.43% B Group, Inc. 2.29% GREAT POINT PARTNERS LLC 3Y 7Y 2.24% Stonepine Capital Management, LLC 3Y 7Y 1.68% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.56% Privium Fund Management B.V. 3Y 1.51% Rock Springs Capital Management LP 3Y 7Y 1.49% Palo Alto Investors LP 3Y 7Y 1.48% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 1.34% Krensavage Asset Management, LLC 3Y 7Y 1.22%
← Back to Bridgefront Capital, LLC Holdings